In November 2018, the US Food and Drug Administration (FDA) issued a Safety Announcement warning about rare but serious instances of stroke and blood vessel wall tears in multiple sclerosis patients who have received Lemtrada<unk> , mostly occurring within 1 day of initiating treatment and leading in some cases to permanent disability and even death. In addition to the 13 cases to which the FDA Safety Announcement refers, a further 5 cases of spontaneous intracranial haemorrhage have been retrospectively identified from four US multiple sclerosis centres in correspondence published online in February 2019. On 12 April 2019, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) reported that it has started a review of the multiple sclerosis medicine Lemtrada<unk>  following new reports of immune-mediated conditions and of problems with the heart and blood vessels with this medicine, including fatal cases. PRAC advised that while the review is ongoing, Lemtrada should only be started in adults with relapsing-remitting multiple sclerosis that is highly active despite treatment with at least two disease-modifying therapies (a type of multiple sclerosis medicine) or where other disease-modifying therapies cannot be used. PRAC further advised that patients being treated with Lemtrada who are benefitting from it may continue treatment in consultation with their doctor. Very common adverse reactions associated with<unk>  infusion in MS patients include upper respiratory tract and urinary tract infections, herpes virus infections, lymphopenia, leucopenia, changes in thyroid function, tachycardia, skin rashes, pruritus, pyrexia, and fatigue. The Summary of Product Characteristics provided in the electronic Medicines Compendium eMC further lists common and uncommon adverse reactions that have been reported for Lemtrada, which include serious opportunistic nocardial infections and cytomegalovirus syndrome.<unk>  can also precipitate autoimmune disease through the suppression of regulatory T cell populations and/or the emergence of autoreactive B-cells. Cases of multiple sclerosis reactivation/relapse have also been reported
Alemtuzumab
Ruxolitinib
Rituximab
Lenalidomide
Imatinib
Ibrutinib
Bosutinib
Ponatinib